Australia's most trusted
source of pharma news
Posted 24 November 2021 AM
AstraZeneca's new Covid therapy Evusheld will need to hustle for market share in Australia if it wins provisional approval from the TGA, according to new research.
Data analytics company GlobalData has warned "on expected successful provisional approval and launch in early 2022" the company faces competition with a "crowded COVID-19 armory" of monoclonal antibody (mAb) and oral antiviral therapies.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.